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Silicon (Si) is the most abundant element present in the Earth's crust besides oxygen. However, the exact biological
roles of silicon remain unknown. Moreover, the ortho-silicic acid (H4SiO4), as a major form of bioavailable silicon for
both humans and animals, has not been given adequate attention so far. Silicon has already been associated with
bone mineralization, collagen synthesis, skin, hair and nails health atherosclerosis, Alzheimer disease, immune
system enhancement, and with some other disorders or pharmacological effects. Beside the ortho-silicic acid and
its stabilized formulations such as choline chloride-stabilized ortho-silicic acid and sodium or potassium silicates (e.g.
M2SiO3; M= Na,K), the most important sources that release ortho-silicic acid as a bioavailable form of silicon are:
colloidal silicic acid (hydrated silica gel), silica gel (amorphous silicon dioxide), and zeolites. Although all these
compounds are characterized by substantial water insolubility, they release small, but significant, equilibrium
concentration of ortho-silicic acid (H4SiO4) in contact with water and physiological fluids. Even though certain
pharmacological effects of these compounds might be attributed to specific structural characteristics that result in
profound adsorption and absorption properties, they all exhibit similar pharmacological profiles readily comparable
to ortho-silicic acid effects. The most unusual ortho-silicic acid-releasing agents are certain types of zeolites, a class
of aluminosilicates with well described ion(cation)-exchange properties. Numerous biological activities of some
types of zeolites documented so far might probably be attributable to the ortho-silicic acid-releasing property. In
this review, we therefore discuss biological and potential therapeutic effects of ortho-silicic acid and ortho-silicic
acid -releasing silicon compounds as its major natural sources.
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Silicon (Si) is the most abundant element (27.2%)
present in the earth's crust following oxygen (45.5%) [1].
Silicon is known for a number of important chemical
and physical properties, i.e. semiconductor property that
are used in various scientific and technical applications.
These Si features, along with structural complexity of its
compounds, have attracted researchers from the earliest
times [2]. In particular, silicon dioxide or silica (SiO2) is
the most studied chemical compound following water,
and the most important Si-containing inorganic sub-
stance [1]. Formally, silica (SiO2) is a silicic acid* Correspondence: sandrakp@biotech.uniri.hr
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reproduction in any medium, provided the oranhydride of monomeric ortho-silicic acid (H4SiO4),
which is water soluble and stable in highly diluted aque-
ous solutions. Moreover, several “lower” hydrated forms
of ortho-silicic acid exist in aqueous solutions as well in-
cluding meta-silicic acid (H2SiO3 or lower oligomers like
di-silicic (H2Si2O5) and tri-silicic acids (H2Si3O7) includ-
ing their hydrated forms pentahydro-silicic (H10Si2O9),
and pyro-silicic acids (H6Si2O7) [1]. These are water sol-
uble, formed in reversible equilibrium reactions from
H4SiO4 and stable in diluted aqueous solutions. During
a prolonged storage period, at increased concentration
or in an acidic environment, these low molecular silicic
acids undergo further condensation by cross-linking and
dehydration. This process results in formation of poly-
silicic acids chains of variable composition [SiOx(OH)4-2x]
and complex structure [1]. The end product is a jelly-liketd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Zeolite A structure: an assembly of framework's cages
(tiles). Centre of a tile is the centre of a void in the framework.
Voids are connected with adjacent ones through the large
"windows" which are faces of tiles.
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ferred as “colloidal silicic acid” or “hydrated silica gel”).
Further condensation follows which is accompanied by
dehydration yielding less hydrated silicon dioxide (SiO2)
phases, also known as “silica gel” or “amorphous silicon
dioxide”.
Lower molecular forms, especially the ortho-silicic
acid (H4SiO4; Figure 1), play a crucial role in delivering
silicon to the living organisms’ cells and thus represent
major sources of silicon for both humans and animals.
Most of the silica in aqueous systems and oceans is
available in the form of H4SiO4, which makes it an im-
portant compound in environmental silicon-chemistry
and biology [3]. In this paper, we critically review the
most recent findings on biological effects of Si and
ortho-silicic acid on animals and human beings. More-
over, we propose that previously observed positive bio-
logical effects of various colloidal silicic acids (various
hydrated silica gels) as well as some zeolites [4-6], e.g.
zeolite A (Figure 2) and clinoptilolite (Figure 3), might
be, at least partially, ascribed to the ortho-silicic acid-re-
leasing property.
Silicon represents the third most abundant trace elem-
ent in the human body [7,8]. For example, it is present
in 1–10 parts-per-million (ppm) in hair [9], nails [10], in
the cornfield epidermis, and in the epicuticle of hair
[11,12]. Silicon is naturally present in food as a silicon
dioxide (SiO2), free ortho-silicic acid (H4SiO4), silicic
acids bounded to certain nutrients, and in the silicate
form. Although silicon is a life-important micronutrient
mineral, in our opinion it has not received adequate at-
tention. Considering the abundance of silicon, both in
the nature and humans, it is expected that it should play
an important role in human and animal health.Figure 1 Chemical 3D structure of Si(OH)4.Silicon bioavailability and consumption
Presently, many biological roles of silicon remain un-
known [13]. Consequently, the recommended daily silicon
intake (RDI) has not yet been set [13,14]. Considering the
risk assessment of amorphous silicon dioxide as common
silicon source (e.g. food additive E551), the safe upper in-
take level (UIL) may be estimated as 700 mg/day for
adults, that is the equivalent to 12 mg silicon/kg bw/day
for a 60 kg adult [15]. These numbers refer to theFigure 3 Microporous crystal structure of clinoptilolite.
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of silicon (as H4SiO4) are actually released in the gastro-
intestinal (GI) tract and subsequently absorbed in the sys-
temic circulation. Due to lack of data, it is difficult to set a
recommended upper intake level for silicon. Moreover, lit-
tle information on the intake of dietary silicon by humans
is available. A mean intake of daily silicon has been
reported in Finland [16], (29 mg silicon/day) and in a typ-
ical British diet (20–50 mg silicon/day) [17-19]. This cor-
responds to 0.3-0.8 mg/silicon/kg bw/day for a 60 kg
person. These data are in the same range as the estimated
mean intakes of silicon in the USA (30 and 33 mg silicon/
day in men, and 24 and 25 mg silicon/day in women, re-
spectively) [8]. Silicon intake decreases with age to less
than 20 mg silicon/day (18.6 ± 4.6 mg silicon/day for eld-
erly British woman in an unrelated randomised controlled
intervention study) [20].
Generally, silicon is abundantly present in foods
derived from plants such as: cereals, oats, barley, white
wheat flour, and polished rice. In contrast, silicon levels
are lower in animal foods including meat or dairy pro-
ducts. Furthermore, silicon is present in drinking wa-
ters, mineral waters, and in beer as well [17]. However,
Jugdaohsingh et al. [21] raised some doubt on utilisation
of silicon from drinking water in an animal rat study as
no significant differences were found in the silicon bone
concentration when the drinking water was supplemen-
ted with silicon in the ortho-silicic acid form. Indeed,
the major sources of silicon in the typical Western hemi-
sphere diet comes from cereals (30%), followed by fruits,
beverages and vegetables, which altogether comprise
around 75% of total silicon intake [20]. Even though
plant food contains high levels of silicon, its bioavailabil-
ity from these sources is questionable, due to poor
solubility of actual silicon forms present in these foods
[18,19,22]. Efficient absorption in the GI tract would re-
quire their breakdown to soluble species such as ortho-
silicic acid, present in drinking and mineral waters in the
range of 2 to 5 mg silicon/L [23] and in beer ranging
from 9 to 39 mg silicon/L [18,24]. Absorption studies
indicate that the ortho-silicic acid is a main readily
bioavailable source of silicon for humans, whereas its
higher polymers are not of significant absorbability [25].
In a placebo-controlled study on eight volunteers,
Jugdaohsingh et al. [25] showed that 53% of adminis-
tered ortho-silicic acid is excreted in the urine, whereas
the ingestion of polymeric silicic acid causes only a
marginal increase of silicon in the urine. This result sub-
stantiates the statement that polymeric silicic acids and
amorphous silicon dioxide are of poor bioavailability.
Besides the ortho-silicic acid, water soluble silicates are
bioavailable silicon forms as well. For instance, pharma-
ceutically acceptable alkali metals silicates (M2SiO3; M=
Na, K) in adequately diluted aqueous solutions, releaseortho-silicic acid (H4SiO4) upon contact with stomach
hydrochloric acid (HCl). Popplewell et al. [26] employed a
tracer dose of radiolabelled ammonium silicate to measure
total uptake and urine excretion. Their results revealed
that 36% of ingested dose was absorbed and completely
excreted in urine within 48h. However, elimination oc-
curred in two steps where the major dose (90%) has been
excreted within the first 2.7 hours. They suggested that
excess silicon is eliminated from the body through two
distinct processes, differing significantly in the duration.
The ‘slower process’ is thought to include the intracellular
uptake and release of silicon, whilst the ‘faster process’
probably includes retention of silicon in the extracellular
fluids [26]. These data report on increased silicon levels in
serum upon consumption of silicon-rich food [7,27],
showing that at least some silicon is available from food as
well. Indeed, selective silicon deprivation in rats showed a
significant drop of urinary silicon excretion and fasting
silicon serum concentration, suggesting that the rats ac-
tively regulate silicon levels via urinary conservation, per-
haps through renal re-absorption [21]. Most of silicon
present in the serum is filtered by the kidney [7,28] sug-
gesting the kidney as its major excretion route; silicon
levels in serum correlate with those in urine. However, it
is still not clear how and if the body can efficiently retain
adequate doses of silicon.
In concentrated solutions, ortho-silicic acid (H4SiO4)
has to be stabilized to avoid its polymerization into poly-
silicic acids and eventually into silica gel, resulting in a
decreased silicon bioavailability. This issue has been
solved in the field of pharmaceutical technology by use
of choline chloride in aqueous glycerol solution. This
resulted in development of a liquid formulation known
as choline-stabilized ortho-silicic acid (ch-OSA). Choline
chloride-stabilized ortho-silicic acid is not a new chem-
ical entity of ortho-silicic acid, but a complex of H4SiO4
and choline chloride formed by several possible hydro-
gen bonds between these two compounds. Subsequently,
from the standpoint of nutrition and pharmacology, the
effects of ch-OSA must involve effects of both H4SiO4
and choline chloride rather than a new chemical entity.
Due to a possible impact of choline chloride on the
chemical stability of H4SiO4, certain specific biological
effects different from those of a pure ortho-silicic acid or
its immediate releasing compounds (e.g. sodium silicate),
must be taken in account. Ch-OSA has been approved
for human consumption and is known to be non-toxic.
Its lethal doses (LD) exceed 5000 mg/kg bw in humans
[29] and 6640 mg/kg bw in animals [30]. The ch-OSA
represents the most bioavailable source of silicon
[22,29]. Moreover, in a randomized placebo-controlled
study [29], the bioavailability of ch-OSA during maternal
transfer to the offspring was investigated in a supple-
mentation study with pigs. The authors correlated
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of weanling piglets from supplemented sows and mater-
nal transfer of absorbed silicon between sows and their
offspring during lactation with high bioavailability of sili-
con from ch-OSA. Importantly, highly bioavailable sili-
con from ch-OSA did not altered calcium, phosphorus
and magnesium levels in blood.
Therapeutic and biological effects of ortho-silicic
acid and certain ortho-silicic acid-releasing
compounds
It was reported that silicon is connected with bone
mineralization and osteoporosis [31], collagen synthesis
and ageing of skin [11], condition of hair and nails [32],
atherosclerosis [33,34], Alzheimer disease [9,35,36], as
well as with other biological effects and disorders. Trace
minerals are known to generally play a vital role in the
human body homeostasis [37] and the serum levels of
silicon are similar to other trace elements, i.e. of iron,
copper, and zinc [38]. Silicon is excreted through the
urine in similar orders of magnitude as calcium. Some
researches claim that silicon does not act as a protein-
bounding element in plasma and is believed to exist
almost entirely as un-dissociated monomeric ortho-
silicic acid [28]. While early analyses showed that serum
contains 50–60 μg silicon/dL [38,39], more recent ana-
lyses indicate that human serum contains 11–25 μg sili-
con/dL, or levels ranging between 24 and 31 μg/dL
(8.5 and 11.1 μmol/L), detected by absorption spectrom-
etry in large population groups [40]. Interestingly, preg-
nant women had very low serum silicon concentrations
(3.3-4.3 μg/dL) in comparison with infants that have
high concentrations between 34 and 69 μg/dL [27,41].
Moreover, silicon concentrations in serum showed a sta-
tistically significant age and sex dependency, as it seems
that silicon concentrations decrease with age, especially
in woman [40].
Biological importance of silicon might be analysed in
the context of its bio-distribution in the body. For
example, the highest silicon concentration has been
measured in connective tissues, especially in the aorta,
tracheas, bone, and skin. Low levels of silicon in the
form of ortho-silicic acid [42-44] may be found in liver,
heart, muscle, and lung [45]. It is therefore plausible to
assume that observed decrease of silicon concentration
in the ageing population may be linked to several degen-
erative disorders, including atherosclerosis. Supplemen-
tation of the regular diet with bioavailable forms of
silicon may therefore have a therapeutic potential in-
cluding prevention of degenerative processes. Several
experiments have already confirmed this hypothesis. For
example, in a controlled animal study, spontaneously
hypertensive rats had lower blood pressure upon supple-
mentation with soluble silicon [44], whilst silicondeficiency in animals has been found to be connected
with bone defects and impaired synthesis of connective
tissue compounds, such as collagen and glycosaminogly-
cans [46-48]. It is therefore reasonable to assume that
silicon deficiency or lower bioavailability may be linked
to problems with bone structure and collagen produc-
tion. Moreover, silicon was shown to be uniquely localized
in active growth areas in young bones of animals where a
close relationship between silicon concentration and the
degree of mineralization has been assessed [46,49]. Studies
confirmed the essential role of silicon in the growth
and skeletal development of chicks that during silicon
deprivation showed significantly retarded skeletal develop-
ment [50]. Experimental silicon deprivation in rats [51-53]
and chicks [46,47] demonstrated striking effects on ske-
letal growth and bone metabolism as well. On the other
hand, the controlled animal study of Jugdaohsingh et al.
[21] showed no profound effects of a silicon-deficient diet
on the bone growth and skeletal development in rats. Sili-
con concentrations in the tibia and soft tissues did not dif-
fer from those in rats on a silicon-deficient diet where the
silicon was supplemented in drinking water. Nevertheless,
silicon levels in tibia were much lower compared to the
reference group fed by a silicon rich diet. Body and bone
lengths were also found to be lower in comparison with
the reference group, while reduction in bone growth plate
thickness was found in silicon deprived rats [21].
Moreover, Reffit et al. [54] found that ortho-silicic acid
stimulates collagen type 1 synthesis in human osteoblast-
like cells and skin fibroblasts and enhances osteoblastic
differentiation in the MG-63 cells in vitro. Ortho-silicic
acid did not alter collagen type 1 gene expression, but it
modulated the activity of prolyl hydroxylase, an enzyme
involved in the production of collagen [55]. Similarly,
Schütze et al. [56] reported that the zeolite A stimulated
DNA synthesis in osteoblasts and inhibited osteoclast-
mediated bone resorption in vitro. This is probably at-
tributable to the ortho-silicic acid-releasing property of
zeolite A.
The mechanism underlying observed biological effects
of silicon may probably be ascribed to its interrelation-
ships with other elements present in the body such as
molybdenum [57] aluminium [9,35,58,59], and calcium
[46,49,50]. For instance, it was proven that silicon levels
are strongly affected by molybdenum intake, and vice
versa [59]. Furthermore, silicon accelerates the rate of
bone mineralization and calcification as shown in
controlled animal studies, in a similar manner that was
demonstrated for vitamin D [11,50]. It is well known
that vitamin D increases the rate of bone mineralization
and bone formation [60], and that its deficiency leads to
less mature bone development. Vitamin D is known
to be important in calcium metabolism, but silicon-
deficient cockerels’ skulls in a controlled animal study
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ive of the vitamin D dietary levels suggesting a vitamin
D-independent mechanism of action [61]. Jugdaohsingh
et al. [21] found that silicon supplementation in drinking
water did not significantly altered silicon concentrations
in bones and suggested that some other nutritional co-
factor is required for maximal silicon uptake into bone
and that this co-factor was absent in rats fed with a low-
silicon diet compared to the reference group fed by a
silicon-rich diet. They suggested vitamin K as such
co-factor, which is important in bone mineralisation
through carboxylation of osteocalcin, and whose defi-
ciency might influence incorporation of minerals such as
silicon in the bones.
Osteoporosis
Osteoporosis is among leading causes of morbidity and
mortality worldwide [62]. It is defined as a progressive
skeletal disorder, characterised by low bone mass (osteo-
penia) and micro-architectural deterioration [63]. Inte-
restingly, the administration of silicon in a controlled
clinical study induced a significant increase in femoral
bone mineral density in osteoporotic women [31]. Direct
relationship between silicon content and bone formation
has been shown by Moukarzel et al. [64]. They found a
correlation between decreased silicon concentrations in
total parenterally fed infants with a decreased bone
mineral content. This was the first observation of a
possible dietary deficiency of silicon in humans. A ran-
domized controlled animal study on aged ovariecto-
mized rats revealed that long-term preventive treatment
with ch-OSA prevented partial femoral bone loss and
had a positive effect on the bone turnover [65]. Dietary
silicon is associated with postmenopausal bone turnover
and bone mineral density at the women's age when the
risk of osteoporosis increases. Moreover, in a cohort
study on 3198 middle-aged woman (50–62 years) it was
shown that silicon interacts with the oestrogen status
on bone mineral density, suggesting that oestrogen sta-
tus is important for the silicon metabolism in bone
health [66].
Skin and hair
Typical sign of ageing skin is fall off of silicon and hyalur-
onic acid levels in connective tissues. This results in loss of
moisture and elasticity in the skin. Appearance of hair and
nails can also be affected by lower silicon levels, since they
are basically composed of keratin proteins. As previously
discussed, ortho-silicic acid may stimulate collagen pro-
duction and connective tissue function and repair. For ex-
ample, Barel et al. [67] conducted experiments on females,
aged between 40–65 years, with clear clinical signs of
photo-ageing of facial skin. Their randomized double-
blinded placebo-controlled study illustrates positive effectsof ch-OSA taken as an oral supplement on skin micro
relief and skin anisotropy in woman with photo-aged skin.
Skin roughness and the difference in longitudinal and lat-
eral shear propagation time decreased in the ch-OSA
group, suggesting improvement in isotropy of the skin. In
addition, ch-OSA intake positively affected the brittleness
of hair and nails. Oral supplementation with ch-OSA had
positive effects on hair morphology and tensile strengths,
as shown in a randomized placebo-controlled double blind
study by Wickett et al. [68].
Alzheimer disease
Aluminium (as Al3+ ion) is a well-known neurotoxin.
Aluminium salts may accelerate oxidative damage of
biomolecules. Importantly, it has been detected in neu-
rons bearing neurofibrillary tangles in Alzheimer's and
Parkinson's disease with dementia as shown in con-
trolled studies [69,70]. Amorphous aluminosilicates have
been found at the core of senile plaques in Alzheimer's
disease [69,71], and have consequently been implicated
as one of the possible causal factors that contribute to
Alzheimer’s disease. Since aluminosilicates are water
insoluble compounds, the transport path to the brain is
still not well understood. By reducing the bioavailability
of aluminium, it may be possible to limit its neuroto-
xicity. Consumption of moderately high amounts of beer
in humans and ortho-silicic acid in animals has shown
to reduce aluminium uptake from the digestive tract
and slow down the accumulation of this metal in the
brain tissue [36,72]. Silicic acid has also been found
to induce down-regulation of endogenous antioxidant
enzymes associated with aluminium administration and
to normalize tumour necrosis factor alpha (TNFα)
mRNA expression [35]. Although the effect of silicic acid
on aluminium absorption and excretion from human
body produced conflicting results so far as shown in an
open-label clinical study [7], in a controlled clinical
study it was shown that silicic acid substantially reduces
aluminium bioavailability to humans [73]. In fact, it was
already found that silicon reduces the aluminium tox-
icity and absorption in some plants and animals that
belong to different biological systems [74-76]. This is
possible as silicon competes with aluminium in bio-
logical systems such as fresh water, as suggested by
Birchall and Chappell study perfomed on the geochem-
ical ground [77], and later confirmed by Taylor et al. in
randomized double blind study [78]. They found that
soft water contains less silicic acid and more aluminium,
while hard waters contain more silicic acid and less
aluminium.
Removal of aluminium from the body and its reduced
absorption by simultaneous administration of silicic acid
was tested and proven by Exley et al. in controlled cli-
nical study [59]. They showed reduced urinary excretion
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trace elements such as iron in persons to whom silicic
acid-rich mineral water was administered. Moreover,
they documented that regular drinking of a silicon-rich
mineral water during a period of 3 months significantly
reduced the body burden of aluminium. Similar results
were obtained by Davenward et al. [79] who showed that
silicon-rich mineral waters can be used as a non-invasive
method to reduce the body burden of aluminium in both
Alzheimer's patients and control group by facilitating the
removal of aluminium via the urine without any concomi-
tant effect. They also showed clinically relevant improve-
ments of cognitive performances in at least 3 out of 15
individuals with Alzheimer disease. This implies a possible
use of ortho-silicic acid as long-term non-invasive therapy
for reduction of aluminium in Alzheimer's disease
patients. The mechanism through which aluminium bio-
availability reduction occurs involves interaction between
aluminium species and ortho-silicic acid where highly
insoluble hydroxyaluminosilicates (HAS) forms are pro-
duced [77,80]. This process makes aluminium unavailable
for absorption.
Immunostimulatory effects
Quartz as a form of crystalline silicon dioxide has been
connected with severe negative biological effects. How-
ever, in controlled studies on mouse and rats it was
shown that sub-chronic and short-term exposure to this
compound can actually have beneficial effects on re-
spiratory defence mechanisms by stimulating immune
system through the increase of neutrophils, T lympho-
cytes and NK cells. It also activates phagocytes and con-
sequently additional ROS production [81-83] which can
help the pulmonary clearance of infectious agents. In
rats, crystalline silica caused proliferation and activation
of CD8+ T cells and, to a lesser amount, of CD4+ T cells.
Recently, an “anionic alkali mineral complex” BarodonW
has shown immunostimulatory effects in horses [84],
pigs [85] and other animals. BarodonW is a mixture of
sodium silicate (M2SiO3, M= Na,K) and certain metal
salts in an alkaline solution (pH= 13.5), where sodium-
silicate (sodium water glass) represents 60% of the total
content. In a placebo-controlled experiment in pigs, the
immunostimulatory effect of BarodonW was assessed by
measurement of proliferation and activation of porcine
immune cells, especially CD4+ CD8+ double-positive
(dpp) T lymphocytes in peripheral blood and in the sec-
ondary lymphoid organ [85]. As this type of T lympho-
cyte cells are characterized by a specific memory cell
marker CD29, they may play a role during activation of
secondary immune responses as shown in a cross-
sectional and longitudinal study on pigs [86]. Moreover,
BarodonW acted mainly on the lymphoid organs, imply-
ing a role in antigenic stimulation of immune tissues[85]. BarodonW induced increased levels of MHC-
II lymphocytes and non-T/non-B (N) cells as well along
with increased stimulatory mitogen activity including
the activity of PHA, concanavalin A, and pokeweed
mitogen [85,87]. In a placebo-controlled experiment on
pigs, it was shown that this mineral complex exerts an
adjuvant effect with hog cholera and Actinobacillus
pleuropneumoniae vaccines by increasing the antibody
titres and immune cell proportions [88]. Moreover,
BarodonW showed nonspecific immunostimulating effects
in racing horses and higher phagocytic activity against
Staphylococcus equi subsp. equi and Staphylococcus
aureus as well in a controlled study [84]. Administration
of BarodonW in horse herds reduced many clinical com-
plications, including stress-induced respiratory disease,
suggesting activation of immune cell populations simi-
larly to the treatment with inactivated Propionibacterium
acnes [89,90]. The exact mechanism of BarodonW immu-
nostimulatory effect is not known, although it has been
suggested that sodium silicate, the main mineral ingredient,
might be responsible for the observed immune-enhancing
properties. Indeed, sodium silicate is known to decompose
quantitatively into bioavailable ortho-silicic acid (H4SiO4)
in the acidic gastric juice (HCl), and as such being absorbed
in the body. In this manner, presumably all observed
pharmacological effects of BarodonW are actually originated
from the ortho-silicic acid.
Pure sodium metasilicate (Na2SiO3) also bears immu-
nostimulatory effects and acts as a potent mitochondria
activator [91]. Dietary silicon in the form of sodium
metasilicate activates formation of ammonia by elevating
mitochondrial oxygen utilisation as shown in a con-
trolled animal experiment [91]. These findings further
corroborate the hypothesis that sodium silicate might be
responsible for immunostimulatory effects of BarodonW.
Once again, the pharmacologically active species was
ortho-silicic acid released upon the action of stomach
hydrochlorid acid on sodium metasilicate.
Zeolites as a source of ortho-silicic acid
Zeolites are a class of aluminosilicates of general formula
(Mn+)x/n[(AlO2)x(SiO2)y]•mH2O, wherein M represents
a positively charged metal ion such as sodium (Na+), po-
tassium (K+), magnesium (Mg2+), or calcium (Ca2+).
Zeolites are crystalline aluminosilicates with open 3D
framework structures built of SiO4 and AlO4 tetrahedra
linked to each other by sharing all the oxygen atoms to
form regular intra-crystalline cavities and channels of
molecular dimensions [92]. The positively charged metal
ions (e.g. Na+, K+, Ca2+, Mg2+) are positioned in these
cavities of aluminosilicate skeleton which are termed as
micro- (2–20 Å), meso- (20–50 Å), and macro-(50–100
Å) -pores. These ions are readily exchangeable in con-
tact with aqueous solution of other positively charged
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characteristic of zeolites is the base of their ion (cation)-
exchange property [93].
At present, 191 unique zeolite frameworks have been
identified [94], while over 40 naturally occurring zeolite
frameworks have been described. Zeolites have been
widely employed in chemical and food industries, agri-
culture, and environmental technologies as adsorbents,
absorbents, adsorbent filter-aids, ion-exchangers, cata-
lysts, active cosmetic and pharmaceutical ingredients,
soil improvers, etc. [95-103]. Besides, zeolites exhibit a
number of interesting biological activities [5,104,105]
(Figure 4). For example, nontoxic natural zeolite clinop-
tilolite affects tumour cells proliferation in vitro and
might act as an adjuvant in cancer therapy [105]. Katic
et al. [106] confirmed that clinoptilolite influences cell
viability, cell division, and cellular stress response that
results in antiproliferative effect and apoptosis induction
in vitro. Obtained results demonstrated that clinoptilo-
lite biological effect on tumour cells growth inhibition
might be a consequence of adsorptive and ion-exchange
characteristics that cause adsorption of some serum
components by clinoptilolite [106]. Similarly, clinopti-
lolite showed antiviral effects in vitro and a potential
in antiviral therapy either for local skin application
against herpesvirus infections or oral treatment of
adenovirus or enterovirus infections [107]. The anti-
viral mechanism is probably non-specific and is based
on adsorption of viral particles on external cavities at
the clinoptilolite surface rather than a consequence of
ion-exchange properties.Figure 4 Biomedical application of zeolites (adopted from: K Pavelic,
135. Amsterdam: Elsevier, 2001, p 170).Each zeolite particle acts like a large inorganic mo-
lecule and acts as a molecular sieve with a potential in
molecular medicine in molecular medicine. Their pores
are indeed, rather small (less than 2 nm to 50 nm) [108],
and these structural similarities between the cages of
zeolites and binding sites of enzymes resulted in
development of zeolite structures that mimic enzyme
functions [108], e.g. haemoglobin, cytochrome P450 or
iron-sulphur proteins [109].
Important data on biological zeolites fate (Figure 5)
and effects in vivo have been widely reported so far in
the scientific literature. For example, it was shown that
zeolites bear detoxifying and decontaminant properties
when added to animal diets, reducing levels of heavy
metals (e.g. lead, mercury, and cadmium) and various
organic pollutants, i.e. radionuclides (Figure 6) and
antibiotics [108]. Furthermore, zeolites have been suc-
cessfully utilized for haemodialysis, for cartridges in hae-
moperfusions, for wound healing, and surgical incisions
[108]. For instance, QuikClot and Zeomic formulations
are already being marketed for haemorrhage control
[110] and dental treatment [5], respectively.
Several toxicological studies proved that certain nat-
ural zeolite, e.g. clinoptiolite are non-toxic and com-
pletely safe for use in human and veterinary medicine
[105]. In vitro and in vivo controlled animal studies have
shown that clinoptilolite is an inert substance that may
cause, in some instances, only moderate but not pro-
gressive fibrosis or mesothelioma [111]. This effect
might be attributed to side-substances present in natural
zeolites, e.g. silica or clay aluminosilicates [112]. ItM Colic, B Subotic. In: Studies in Surface Science and Catalysis, Vol.
Figure 5 Structural and biochemical changes of zeolites in the digestive system (by courtesy from Application of natural zeolites in
medicine and cosmetology – ZEOMEDCOS. SWB, Baku-London, 2010).
Jurkić et al. Nutrition & Metabolism 2013, 10:2 Page 8 of 12
http://www.nutritionandmetabolism.com/content/10/1/2should be also stated that some zeolites might be ex-
tremely dangerous for human health and exert negative
biological effects. For example, erionite, a fibrous type of
natural zeolite, causes a high incidence of mesotheliomas
and fibrosis in humans and experimental animals [113].
Animal studies have also shown the possibility of zeo-
lite A (sodium aluminosilicate) as a viable source of sili-
con [4,6,114]. The latter is one of known zeolites that
breaks down into bioavailable ortho-silicic acid (H4SiO4)
in the digestive system. This property arises from the
structure of zeolite A which is characterized by the same
number of aluminium and silicon atoms in zeolite A[115]. Zeolite A is hydrolysed at low pH (stomach
hydrochloric acid) into ortho-silicic acid (H4SiO4) and
aluminium ions (Al3+). These are combined back to the
amorphous aluminosilicate. Such process readily provides
additional source of bioavailable silicon to the organism
[114,116]. Indeed, randomized placebo-controlled studies
on dogs [114] proved that silicon is absorbed upon oral
administration of zeolite A. Comparable results have been
obtained in a randomized placebo-controlled research on
horses as well [6]. Addition of zeolite A to the diet of
young racing quarter horses have resulted in decreased
skeletal injury rates and better training performance [117].
Figure 6 The fate of isotope labelled activated clinoptilolite-zeolite in the gastro-intestinal tract (by courtesy from Application of
natural zeolites in medicine and cosmetology – ZEOMEDCOS. SWB, Baku-London, 2010).
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http://www.nutritionandmetabolism.com/content/10/1/2However, increased bone formation was found in rando-
mized controlled studies on broodmare horses [118], but
not in yearling horses [119]. Food supplementation with
zeolite A in calves showed no changes in bone architec-
ture or mechanical properties [120]. However, in a
controlled study Turner et al. [120] showed increased alu-
minium content in the bone and cartilage of zeolite A-fed
calves which is an important safety issue for the zeolite A
therapeutic usage.
Conclusion
In conclusion, we believe that ortho-silicic acid (H4SiO4)
might be a prominent therapeutic agent in humans.
Some potential therapeutic and biological effects on
bone formation and bone density, Alzheimer disease,
immunodeficiency, skin, hair, and nails condition, as well
as on tumour growth, have already been documented
and are critically discussed in the presented paper. Acid
forms of ortho-silicic acid include: choline-chloride-
stabilized ortho-silicic acid (ch-OSA) as a specific
pharmaceutical formulation of H4SiO4, simple water
soluble silicate salts such as sodium silicate (E550;Na2SiO3) or potassium silicate (E560; K2SiO3), and cer-
tain water-insoluble forms that, upon contact with stom-
ach juice (HCl), release small, but biologically significant
amounts of ortho-silicic acid. The latter involves: col-
loidal silicic acid (hydrated silica gel), amorphous silicon
dioxide (E551), certain types of zeolites such as zeolite A
(sodium aluminosilicate, E554; potassium aluminosili-
cate, E555; calcium aluminosilicate, E556), and the na-
tural zeolite clinoptilolite. However, for some of the
above-proposed therapeutic perspectives of both ortho-
silicic acid and ortho-silicic acid -releasing derivatives,
additional insights into biological mechanisms of action
and larger studies on both animals and humans are
required.
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